Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
2016
Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macrophage kinase, restores T cell–dependent antitumor immune responses, thereby inhibiting PDAC growth and improving responsiveness to standard-of-care chemotherapy. We report that PDAC tumor growth depends on cross-talk between B cells and FcRγ+ tumor–associated macrophages, resulting in TH2-type macrophage programming via BTK activation in a PI3Kγ-dependent manner. Treatment of PDAC-bearing mice with the BTK inhibitor PCI32765 (ibrutinib) or by PI3Kγ inhibition reprogrammed macrophages toward a TH1 phenotype that fostered CD8+ T-cell cytotoxicity, and suppressed PDAC growth, indicating that BTK signaling mediates PDAC immunosuppression. These data indicate that pharmacologic inhibition of BTK in PDAC can reactivate adaptive immune responses, presenting a new therapeutic modality for this devastating tumor type.
Significance: We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. Inhibition of BTK with the FDA-approved inhibitor ibrutinib restores T cell–dependent antitumor immune responses to inhibit PDAC growth and improves responsiveness to chemotherapy, presenting a new therapeutic modality for pancreas cancer. Cancer Discov; 6(3); 270–85. ©2015 AACR .
See related commentary by Roghanian et al., [p. 230][1] .
See related article by Pylayeva-Gupta et al., [p. 247][2] .
See related article by Lee et al., [p. 256][3] .
This article is highlighted in the In This Issue feature, [p. 217][4]
[1]: /lookup/volpage/6/230?iss=3
[2]: /lookup/volpage/6/247?iss=3
[3]: /lookup/volpage/6/256?iss=3
[4]: /lookup/volpage/6/217?iss=3
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
54
References
284
Citations
NaN
KQI